Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 13 Jun 2019 |
| Zealand Pharma announces amendments to its Articles of Association following the granting of warrants | 13 Jun 2019 |
| Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet™ bionic pancreas using dasiglucagion | 6 Jun 2019 |
| Total number of shares and voting rights in Zealand Pharma as of May 31, 2019 | 3 Jun 2019 |
| Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | 28 May 2019 |
| Correction: Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | 28 May 2019 |